Literature DB >> 29740896

GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).

Cristina Rebordosa1, Estel Plana1, Jaume Aguado1, Steven Thomas2, Esther García-Gil3, Susana Perez-Gutthann1, Jordi Castellsague1.   

Abstract

PURPOSE: To evaluate availability of spirometry and symptom data in the Clinical Practice Research Datalink (United Kingdom) to assess COPD severity using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016 definition and comparing it with an algorithm used in other studies.
METHODS: This was a descriptive, noninterventional, secondary database cohort study of patients with COPD aged 40 years or older, who initiated treatment with specific COPD medications. Patients were classified according to COPD severity (1) in GOLD 2016 "ABCD" categories based on symptoms (Medical Research Council dyspnea grade, COPD Assessment Test, breathlessness), percent predicted FEV1, and exacerbation history and (2) as mild, moderate, severe, or very severe based on treatment and exacerbation history.
RESULTS: The study included 63 900 patients with COPD aged 40 years or older that were new users of 1 or more COPD medication of interest. Percent predicted FEV1 was available for 80.9% of patients; symptoms for 75.6% of patients. Classification into GOLD 2016 ABCD categories was possible for 75.6% of the patients. The GOLD 2016 ABCD definition classified more patients under the high-risk categories (22.1%, A; 18.8%, B; 21.3%, C; 37.9%, D) than did the adapted algorithm (7.9%, mild; 48.6%, moderate; 42.1%, severe; 1.4%, very severe).
CONCLUSION: Using our adaptation of the GOLD 2016 COPD severity classification, the information in the Clinical Practice Research Datalink allowed us to ascertain COPD severity in approximately 75% of patients with COPD. Algorithms that include medication use tend to misclassify patients with the extreme COPD severity categories.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  CAT scale; COPD exacerbations; COPD severity assessment; COPD symptoms; global initiative for chronic obstructive lung disease (GOLD); mMRC; percent predicted forced expiratory volume in 1 second (FEV1); pharmacoepidemiology

Mesh:

Substances:

Year:  2018        PMID: 29740896     DOI: 10.1002/pds.4448

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross-sectional study.

Authors:  C T Costiniuk; R Nitulescu; Z Saneei; N Wasef; S Salahuddin; D Wasef; J Young; C de Castro; J P Routy; B Lebouché; J Cox; B M Smith; S Ambroise; C Pexos; M Patel; J Szabo; L P Haraoui; A de Pokomandy; C Tsoukas; J Falutz; R LeBlanc; A Giannakis; C Frenette; M A Jenabian; J Bourbeau; M B Klein
Journal:  HIV Med       Date:  2019-01-08       Impact factor: 3.180

2.  A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.

Authors:  Cristina Rebordosa; Estel Plana; Annalisa Rubino; Jaume Aguado; Alejhandra Lei; Sami Daoud; Nuria Saigi-Morgui; Susana Perez-Gutthann; Elena Rivero-Ferrer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-05-31

3.  Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England.

Authors:  Leah B Sansbury; Kieran J Rothnie; Chanchal Bains; Chris Compton; Glenn Anley; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-09-15

4.  Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety.

Authors:  Samy Suissa; Sophie Dell'Aniello; Pierre Ernst
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-08-30

5.  Percutaneous lung microwave ablation versus lung resection in high-risk patients. A monocentric experience.

Authors:  Paolo Mendogni; Elisa Daffrè; Lorenzo Rosso; Alessandro Palleschi; Ilaria Righi; Rosaria Carrinola; Francesco Damarco; Federico Polli; Annamaria Ierardi; Antonio Arrichiello; Gianpaolo Carrafiello; Mario Nosotti; Davide Tosi
Journal:  Acta Biomed       Date:  2020-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.